NCT00138801已完成3 期
Effect of Intravenous Ceftriaxone and Oral Doxycycline for Lyme Neuroborreliosis. A Randomized Double-blind Comparison
Sorlandet Hospital HF1 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2004年3月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 120
- 试验地点
- 1
研究概览
简要总结
The aim of this study is to compare parenteral ceftriaxone and oral doxycycline in the treatment of neuroborreliosis in a randomized controlled trial.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Diagnostic
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 100 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Neurological symptoms and/or findings consistent with neuroborreliosis and at least one of the following fulfilled:
- •Intrathecal production of borrelia antibodies;
- •White cell count in cerebrospinal fluid (CSF) > 5/mm3;
- •Significant rise in borrelia antibodies in two serum samples collected from a patient with at least 3 weeks interval;
- •Verified acrodermatitis chronica atrophicans.
排除标准
- •Allergy to the contents in the medication, or earlier type I reaction to penicillin.
- •Treatment with cephalosporins, penicillin or tetracyclins during the last 14 days
- •Pregnancy or breastfeeding
- •Age < 18 years
研究组 & 干预措施
1
Active Comparator
Doxycycline
干预措施: Doxycycline (Drug)
2
Active Comparator
cephtriaxone
干预措施: Ceftriaxone (Drug)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
Antibiotic Treatment of Multiple Erythema MigransMultiple Erythema MigransNCT01163994University Medical Centre Ljubljana500
Unknown
不适用
Doxycycline and Ceftriaxone in Suspected Early Lyme NeuroborreliosisSuspected Early Lyme NeuroborreliosisNCT00942006University Medical Centre Ljubljana200
招募中
不适用
Susceptibility of Ceftriaxone on infectionsCTRI/2022/04/041997Alkem Laboratories
Unknown
1 期
Efficacy Of Doxycycline & Versus Rifampin In Treatment Of RhinoscleromaRhinoscleromaNCT05431673Assiut University45
已完成
3 期
Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia Due to S. PneumoniaePneumonia, BacterialNCT00540072Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)